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The aim of the present studywas to perform an in vitro analysis of the antimicrobial and antiproliferative potential of an extract from
Anadenanthera colubrina (Vell.) Brenan (angico) and chemically characterize the crude extract. Antimicrobial action was evaluated
based on the minimum inhibitory concentration (MIC), minimum bactericidal/fungicidal concentration, and the inhibition of
formation to oral biofilm. Cell morphology was determined through scanning electron microscopy (SEM). Six strains of tumor
cells were used for the determination of antiproliferative potential. The extract demonstrated strong antifungal activity against
Candida albicans ATCC 18804 (MIC = 0.031mg/mL), with similar activity found regarding the ethyl acetate fraction. The extract
and active fraction also demonstrated the capacity to inhibit the formation of Candida albicans to oral biofilm after 48 hours, with
median values equal to or greater than the control group, but the difference did not achieve statistical significance (𝑃 > 0.05). SEM
revealed alterations in the cell morphology of the yeast. Regarding antiproliferative activity, the extract demonstrated cytostatic
potential in all strains tested. The present findings suggest strong antifungal potential for Anadenanthera colubrina (Vell.) Brenan
as well as a tendency toward diminishing the growth of human tumor cells.
1. Introduction
The high prevalence rates of adverse oral conditions and
the limitations of available treatment methods have led to
increasing interest among the scientific community in alter-
native therapies [1]. This interest has fueled research into
natural compounds with adequate effectiveness and fewer
adverse effects in the control of oral biofilm, which is
responsible for the development of conditions such as tooth
decay and candidiasis [2].
Bacterial and fungal infections pose a challenge to
researchers and clinicians, especially in immunocompro-
mised patients. This situation is further complicated by the
development of resistance to conventionalmedications on the
part of a large number of microorganisms.Therefore, studies
are needed for the discovery of safe, stable drugs from sources
found in nature that are effective against resistant bacteria and
fungi [3]. Such drugs could also benefit a greater number of
individuals due to the low cost and greater availability [4].
Medicinal plants have become an important source for
the discovery of novel antimicrobial agents. Raw extracts
from plants and isolated substances in these extracts have
demonstrated activity against a number of pathogens [5]. It is
also important to determine the potential of natural products
with biological activity regarding possible harm to normal
cells as well as damage to tumor cells to establish possible
therapeutic uses [6].
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Multidisciplinary studies, especially those uniting phy-
tochemistry and pharmacology, have become increasingly
necessary due to the use of medicinal plants throughout
the world [7]. Anadenanthera colubrina (Vell.) Brenan, com-
monly known as “angico”, is a tree belonging to the subfamily
Mimosoideae (Leguminosae) that occurs in different biomes
in Brazil, Bolivia, Argentina, Paraguay, and Peru [8, 9]. A.
colubrina is reported to be one of the most widely used plants
in folk medicine and is employed to treat respiratory prob-
lems, inflammation, diarrhea, cough, bronchitis, influenza,
and toothache [10–14]. The bark is the most commonly used
part of the plant, the availability of which is not limited by
variations in climatic conditions [15].
The aim of the present study was to perform an in vitro
analysis of the antimicrobial and antiproliferative potential of
the crude extract and fractionated extracts from Anadenan-
thera colubrina (Vell.) Brenan (angico).
2. Materials and Methods
2.1. Preparation of Hydroalcoholic Extract and Fractionation.
A. colubrina was collected in the month of September from
the Bodocongo´ Hills in the city of Queimadas, which is
located in the Borborema tableland of the eastern Cariri
microregion of the semiarid region of the state of Para´ıba,
Brazil (7∘ 22󸀠 25󸀠󸀠S, 35∘ 59󸀠 32󸀠󸀠W). A voucher specimen was
deposited in the Manuel de Arruda Caˆmara Herbarium of
the Para´ıba State University (Campus I, Campina Grande,
Para´ıba, Brazil) under n∘ 667/ACAM.
The bark (100 g) was dried, ground, and immersed in
80% ethanol (250mL) at room temperature for 48 hours.
The resulting mixture was filtered and the residues were
immersed in 80% alcohol two additional times. The three
final liquid phases were concentrated in a rotary evap-
orator and freeze-dried. Liquid-liquid partition was used
to fractionate the extract based on the polarity gradient.
Hexane, chloroform, ethyl acetate, and aqueous fractions
were obtained and submitted to thin-layer chromatography
using anisaldehyde as the reagent. The fractions were then
incubated at 100∘C for five minutes.
2.2. Microorganisms and Susceptibility Test. The following
microorganisms were used: Streptococcus mutans ATCC
25175, Streptococcus sanguinis ATCC 10557, Pseudomonas
aeruginosa ATCC 27853, Enterococcus faecalis ATCC 29212,
and Candida albicans ATCC 18804. Antimicrobial activity
of the hydroalcoholic extract and fractionated extracts of
Anadenanthera colubrina (Vell.) Brenan was identified, by
microdilution in broth, determining theminimum inhibitory
concentration (MIC), minimum bactericidal concentration
(MBC), and minimum fungicidal concentration (MFC) fol-
lowing the norms established by the Clinical and Laboratory
Standards Institute [16, 17].
The test was carried out in 96-well microplates containing
100 𝜇L/well of the specific culture medium (brain heart
infusion (BHI; Difco, Franklin Lakes, NJ, USA) for bacteria
and RPMI 1640 (Angus Buffers & Biochemicals, Niagara
Falls, NY, USA) for yeast). The substances were diluted in
40% alcohol (8mg/mL) and transferred to the first well and
serial dilutionswere then performed to obtain concentrations
between 15.62 and 2000𝜇g/mL. Chlorhexidine 0.12% (Sigma-
Aldrich) and nystatin (Sigma-Aldrich) were used as the
positive controls and 40% alcohol was used as the negative
control. 40% alcohol was tested and showed no antimicrobial
activity against the microorganism studied. The bacterial
inocula (1.0 × 106 colony-forming units (CFU)/mL) and
fungal inocula (5.0 × 103 CFU/mL) were added to the wells
and the plates were incubated at 37∘C for 24 hours. The MIC
was defined as the lowest concentration of the extract or
fraction that inhibited visible microbial growth, which was
confirmed with 0.01% resazurin (Sigma-Aldrich, St. Louis,
MO,USA) for bacteria and by the change in color of theRPMI
1640 for yeast.
For the determination of MBC/MFC, an aliquot (50 𝜇L)
from each well with concentrations greater than the MIC
was subcultured on BHI agar for bacterial and Sabouraud
dextrose agar for yeast and incubated at 37∘C for 24 hours.
MBC andMFCwere defined as the lowest concentration that
inhibited visible growth on the solid medium.
All assays were performed in triplicate in three indepen-
dent experiments. At the end of the tests, the active fraction
of the A. colubrina extract was determined.
2.3. Analysis of Formation to Biofilm. Biofilmswere produced
in untreated 96-well plates. For the evaluation of the for-
mation of microbial cells to the biofilm, 100 𝜇L of a micro-
bial suspension containing 105 CFU/mL (yeast) cultivated
in RPMI with the addition of 2% sucrose was transferred
to the different wells containing concentrations of 15.62 to
2000𝜇g/mL of the hydroalcoholic extract and active fraction.
Theplateswere incubated at 37∘C for 48 hours under agitation
(75 rpm). As the negative control, three wells in each plate
were submitted to the same procedures without the addition
of the treatments. Nystatin was used as the positive control.
All assays were carried out in triplicate in three independent
experiments.
For the quantification of adhered cells, the wells were
rinsed with distilled water and allowed to dry at room
temperature for 45 minutes. An aqueous solution of 1%
crystal violet (200𝜇L) was added to eachwell and left to stand
for 45 minutes. The wells were rinsed again with distilled
water and destained with 200 𝜇L of 95% ethanol. After 45
minutes, 150 𝜇L of the destained solution from each well was
transferred to a new 96-well plate and the amount of crystal
violet was measured in a microplate reader (SpectraMax
340 Tunable Microplate Reader; Molecular Devices Ltd.) at
525 nm. Absorbance values of the substances were subtracted
from that of the negative control to determine the number of
adhered microbial cells [18, 19].
2.4. Analysis of Cell Morphology. Biofilms were formed on
slides (Lab-Tek, Nunc, Naperville, IL, USA) using themethod
described above and treated with the extract and active
fraction at concentrations capable of inhibiting the microbial
growth (MIC/MFC). The cells were fixed in 3% glutaralde-
hyde in a phosphate buffer solution at room temperature
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for 12 hours. The biofilm was then dehydrated in increasing
concentrations of ethanol (50, 70, 90, and 100%), gold
sputtered, and examined using scanning electronmicroscopy
(SEM; JEOL JSM 5600LV, JEOL Tokyo, Japan).
2.5. Antiproliferative Test. The proliferative study involved
human keratinocytes (HaCaT) and six human tumor lines:
NCI-ADR/RES (ovary with phenotype resistance to multi-
ple drugs), 786-O (kidney), NCI-H460 (lung), OVCAR-3
(ovary), HT-29 (colon), and K562 (bone marrow). Cultures
were performed in 5mL of RPMI 1640 medium (Gibco-
BRL, Grand Island, NY, USA) supplemented with 10%
bovine fetal serum (Gibco-BRL, Grand Island, NY, USA),
with the addition of a blend of penicillin and streptomycin
(1000U/mL: 1000mg/mL; 1mL/L RPMI). The cultures were
placed in 96-well plates (100 𝜇L/well) and exposed to the
hydroalcoholic extract and active fraction, diluted in sodium
dimethylsulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO,
USA) at a concentration of 0.1 g/mL, and incubated at 37∘C
in a humid atmosphere with 5% CO
2
for 24 hours. The final
concentration of DMSO did not affect cell viability.
Before (plate T
0
) and after (plate T
1
) the addition of the
sample, the cells were fixed with 50% trichloroacetic acid
and cell proliferation was determined by the quantification of
proteins in a spectrophotometer at 540 nm, using sulforho-
damine B. Based on the concentration-response curve for
each cell line, the GI
50
(concentration of raw hydroalcoholic
extract needed to inhibit growth by 50%) was determined
through a linear regression analysis using the Origin 8.0
program (OriginLab Corporation).
2.6.Determination onTotal Flavonoids, Total Polyphenols, and
Condensed Tannins. For the determination of total flavonoid
content, a 2% aluminum chloride (AlCl
3
) solution was added
to the extract. After 10 minutes, the reading was performed
in a spectrophotometer (ShimadzuUVmini-1240) at 415 nm.
The calibration curve was determined based on solutions of
quercetin. The concentration of flavonoids was expressed in
milligram equivalents of quercetin [20].
For the determination of total polyphenol content, the
Folin-Ciocalteu 1N reagent was added to an aqueous solution
of the extract and the mixture was allowed to stand for
two minutes. An aqueous solution of 20% sodium carbonate
(Na
2
CO
3
) was then added. After 10 minutes, absorbance was
read at 757 nm. The calibration curve was determined based
on solutions of gallic acid. The concentration of polyphenols
was expressed in milligram equivalents of gallic acid [21].
For the determination of the content of condensed tan-
nins, a vanillin solution was added to the extract, followed
by the addition of 37% hydrochloric acid (HCl). The reaction
occurred in test tubes placed in a water bath at a temper-
ature of approximately 20∘C. The reading was performed
at 500 nm. The calibration curve was determined based
on solutions of catechin. The concentration of condensed
tannins was expressed in milligram equivalents of catechin
[22].
All experiments described above were carried out in
triplicate.
Table 1: Minimum inhibitory, bactericidal, and fungicidal concen-
trations of hydroalcoholic extract from Anadenanthera colubrina
(Vell.) Brenan evaluated against bacterial species and Candida
albicans.
Microorganisms
Anadenanthera colubrina (Vell.) Brenan
MIC
(𝜇g/mL)
MBC/MFC
(𝜇g/mL)
Candida albicans
ATCC 18804 31.25 1000
Streptococcus mutans
ATCC 25175 2000 >2000
Streptococcus sanguis
ATCC 10557 2000 >2000
Enterococcus faecalis
ATCC 29212 2000 >2000
Pseudomonas aeruginosa
ATCC 27853 500 1000
Table 2: Minimum inhibitory and fungicidal concentrations of
fractions of hydroalcoholic extract from Anadenanthera colubrina
(Vell.) Brenan evaluated against Candida albicans (ATCC).
Fractions of hydroalcoholic extract from
Anadenanthera colubrina (Vell.) Brenan
MIC
(𝜇g/mL)
MBC/MFC
(𝜇g/mL)
Ethyl acetate 31.25 2000
Hexane 62.5 2000
Chloroform 125 2000
Aqueous 1000 2000
2.7. Statistical Analysis. Statistical analysis was performed
with the data from the test on the inhibition of forma-
tion to oral biofilm (discrete quantitative variable). The
Kolmogorov-Smirnov test revealed nonnormal distribution.
Thus, the comparison of substances was performed with
the nonparametric Kruskal-Wallis test, with the level of
significance set to 5% (𝑃 < 0.05).
3. Results
Table 1 displays the MIC and MBC/MFC for the hydroal-
coholic extract of A. colubrina. The best activity was found
against Candida albicans. Based on this finding, the different
fractions of the extract were only tested on this species
(Table 2). The ethyl acetate fraction achieved the best result
(MIC = 31.25 𝜇g/mL), which demonstrated fungistatic action
similar to that of the crude extract.
The test for the inhibition of the formation to oral biofilm
by the A. colubrina extract and its ethyl acetate fraction
demonstrated equivalent results, with a fair performance
until reaching the MIC (31.25 𝜇g/mL). The median values of
the crude extract and active fraction were higher than those
achieved with nystatin, but the differences did not achieve
statistical significance (𝑃 > 0.05) (Figure 1).
The SEM images demonstrate the effect of the extract
(Figure 2) and its active fraction (Figure 3) at the respective
MIC and MFC on Candida albicans biofilm. These figures
4 Evidence-Based Complementary and Alternative Medicine
Table 3: Distribution of cell growth inhibition (GI
50
) by Anadenan-
thera colubrina (Vell.) Brenan extract tested on human tumor cell
cultures.
Cell lines Anadenanthera colubrina (Vell.) Brenan
GI
50
(𝜇g/mL)
Ovary (NCI-ADR/RES) 61.3
Kidney (786-0) 142.7
Lung (NCI-H460) 80.3
Ovary (OVCAR-3) 131.1
Colon (HT29) 95.8
Leukemia (K562) 5.7
Keratinocytes (HaCaT) 99.7
Mean log GI
50
1.81
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Figure 1: Effect of Anadenanthera colubrina Brenan extract, active
fraction, and nystatin on mature biofilm (48 h).
suggest the occurrence of alteration in cell wall of Candida
albicans, exhibited the occurrence of de-structuring of the cell
morphologywith the use of the test substances, and predomi-
nance of the ovoid blastospores form and few pseudohyphae.
Figure 4 displays effects of nystatin and the negative control.
In the negative control group can be observed the presence of
ovoid blastospores and hyphae.
As the extract and active fraction demonstrated a similar
performance, the antiproliferative test was performed only
with the crude extract.A. colubrinademonstrated nonspecific
cytostatic activity and was capable of diminishing tumor
growth in all cell lines at an approximate concentration
of 250𝜇g/mL. However, the extract did not demonstrate
cytocidal activity. Table 3 displays the 50% growth inhibition
values. Mean Log GI
50
was 1.81 𝜇g/mL.
The phytochemical characterization revealed a high total
polyphenol content (53.18% gallic acid equivalents). Tannin
contentwas 8.77% catechin equivalents and flavonoid content
was 0.28% quercetin equivalents.
4. Discussion
Despite the widespread use ofA. colubrina by the population,
few studies have sought to demonstrate its properties scientif-
ically.The bark of this tree is reported to have effective action
as an anti-inflammatory agent with peripheral antinocicep-
tive activity, indicating the existence of compounds with
potential for the development of drugs for the treatment of
inflammation and pain [23]. The present findings indicate
the antifungal potential of this plant, as the extract and
its active fraction inhibited the growth of Candida albicans
(MIC = 0.31mg/mL), demonstrating strong antimicrobial
activity [24]. A. colubrina also demonstrated a fungistatic
nature, with a high MFC (1 to 2mg/mL), which suggests
the inhibition of the growth of the microorganism without
causing its death
C. albicans biofilm consists of a mixture of yeast, hyphae,
and pseudohyphae [25]. In the maturation phase an increase
in the growth of the hyphae and a reduction in the yeast occur
[25–27]. In the SEM analysis, the A. colubrina demonstrated
the capacity to inhibit the formation of hyphae, with a
predominance of blastospores, demonstrating the suscepti-
bility of the C. albicans biofilm to this plant. Infections by
this microorganism have exhibited increased resistance to
antifungal agents, leading to treatment failures and relapses
[28]. The present findings show the possibility of developing
novel antifungal agents based on A. colubrina, as the extract
and its active fraction demonstrated the capacity to inhibit the
formation ofC. albicans biofilm,with better results than those
achieved with nystatin.The cell wall plays a fundamental role
in nearly all aspects of the biology and cellular pathogenicity
of yeasts, acting as a permeability barrier. Its structure
maintains the shape of the yeast and plays a mediating role in
interactions between the microorganism and its surrounding
environment [29].
After the demonstration of the antimicrobial activity of
a natural product, it is important to determine whether
it also has an antiproliferative effect. Drugs derived from
medicinal plants have played a significant role in the treat-
ment of cancer. Indeed, among all antitumor drugs available
between 1940 and 2002, 40% originated from natural or
semisynthetic products [30]. According to the criteria of
the US National Cancer Institute for the classification of
antiproliferative activity, a product with a mean log GI
50
greater than 1.5 is considered inactive [31]. A. colubrina had
a mean of 1.81, indicating the absence of antiproliferative
activity against the tumor lines tested. However, the extract
demonstrated a tendency toward diminishing cell growth,
especially leukemia-causing cells. An absence of activity
was also found regarding the nontumor line (keratinocytes),
indicating that the extract is not toxic to normal cells. While
not demonstrating cytocidal activity, the extract was capable
of inhibiting cell growth in a nonspecific fashion, which
characterizes the substance as cytostatic.
A. colubrina also demonstrated interesting results regard-
ing Pseudomonas aeruginosa (MIC = 0.5mg/mL). The
emergence of this bacterium as an opportunistic human
pathogen in the last century may be a consequence of
its resistance to antibiotics. P. aeruginosa is considered an
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(a) (b)
Figure 2:Microphotograph (SEM) ofCandida albicans biofilm treated withAnadenanthera colubrina (Vell.) Brenan extract at concentrations
of 31.25 𝜇g/mL (a) and 2000𝜇g/mL (b) (magnification: 5000x).
(a) (b)
Figure 3: Microphotograph (SEM) of Candida albicans biofilm treated with ethyl acetate fraction at concentrations of 31.25 𝜇g/mL (a) and
2000𝜇g/mL (b) (magnification: 5000x).
(a) (b)
Figure 4: Microphotograph (SEM) of Candida albicans biofilm treated with nystatin (a) and negative control (b) (magnification: 5000x).
important source of bacteremia and a predominant cause of
illness and death in patients, such as those with cystic fibrosis
[32].
The phytochemical analysis confirmed the abundance
of phenolic compounds in A. colubrina, which are usually
related to the pharmacological activity of plants. In the
phytochemical screening of the bark of A. colubrina, authors
have found catechins, flavonoids, phenols, saponins, steroids,
tannins, triterpenes, and xanthones, suggesting the partici-
pation of secondary metabolites in the biological activity of
this plant [23]. In the present study, polyphenols accounted
for 53.18% of the extract. It has been suggested that these
substances are capable of causing metabolic instability in
C. albicans and destroying the enzymatic activity of protea-
somes, thereby contributing to reductions in the growth rate
of themicroorganism aswell as the formation andmaturation
6 Evidence-Based Complementary and Alternative Medicine
of the biofilm [33]. The large amount of polyphenols in A.
colubrina may explain the results found in the analysis of
biofilm inhibition.
Further studies are needed to determine the mechanism
of action of A. colubrina on C. albicans. The present results
are promising regarding the antifungal potential of this plant.
It is also important to test this substance with other species of
the genus.
5. Conclusions
The findings of the present study suggest that A. colubrina
has compounds with strong antifungal activity, which are
capable of inhibiting Candida albicans cell growth and the
formation of biofilm by causing considerable morphological
changes in the structure of this microorganism. With regard
to antiproliferative activity, the extract demonstrated the
capacity to diminish the growth of tumor cells and proved
inactive against normal cells. Thus, this plant has potential in
the development of new drugs and its mechanisms of action
merit further investigation.
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